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Review of data and knowledge gaps regarding yellow fever
vaccine-induced immunity and duration of protection
J. Erin Staples 1✉, Alan D. T. Barrett2, Annelies Wilder-Smith3,4 and Joachim Hombach5
Yellow fever (YF) virus is a mosquito-borne flavivirus found in Sub-Saharan Africa and tropical South America. The virus causes YF, a
viral hemorrhagic fever, which can be prevented by a live-attenuated vaccine, strain 17D. Despite the vaccine being very successful
at decreasing disease risk, YF is considered a re-emerging disease due to the increased numbers of cases in the last 30 years. Until
2014, the vaccine was recommended to be administered with boosters every 10 years, but in 2014 the World Health Organization
recommended removal of booster doses for all except special populations. This recommendation has been questioned and there
have been reports of waning antibody titers in adults over time and more recently in pediatric populations. Clearly, the potential of
waning antibody titers is a very important issue that needs to be carefully evaluated. In this Perspective, we review what is known
about the correlate of protection for full-dose YF vaccine, current information on waning antibody titers, and gaps in knowledge.
Overall, fundamental questions exist on the durability of protective immunity induced by YF vaccine, but interpretation of studies is
complicated by the use of different assays and different cut-offs to measure seroprotective immunity, and differing results among
certain endemic versus non-endemic populations. Notwithstanding the above, there are few well-characterized reports of vaccine
failures, which one would expect to observe potentially more with the re-emergence of a severe disease. Overall, there is a need to
improve YF disease surveillance, increase primary vaccination coverage rates in at-risk populations, and expand our understanding
of the mechanism of protection of YF vaccine.
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INTRODUCTION
Yellow fever (YF) virus, a mosquito-borne flavivirus, is present in
tropical areas of Africa and South America. Infection in humans
can produce a hemorrhagic fever and is fatal in 30–60% of persons
with severe disease1,2. Recent decades have witnessed an
unprecedented emergence of YF virus activity, including in highly
urbanized areas where vaccination coverage was low3–5. It has
been recently estimated that roughly 400 million individuals
require vaccination within at-risk zones to potentially prevent
epidemic of the disease though many more might be at risk due
to the recent expansion of risk zones, particularly in Brazil3,6
YF vaccine was first developed in the 1930s after successful
attenuation of the Asibi strain of YF virus to generate the strain
17D7. Today, three substrains (17D-204, 17DD, and 17D-213) are
used as vaccines and are manufactured by six companies, of
which four are prequalified by the World Health Organization
(WHO)8. The vaccine is given as one dose either by subcutaneous
or intramuscular administration, with 80% of vaccine recipients
develop neutralizing antibodies 10 days post immunization and
close to 100% by one month post immunization in clinical trials9.
However, it has been noted that children <2 years of age can have
lower seroconversion rates following a single dose of YF vaccine10.
No human efficacy studies have ever been performed with the
vaccine, but protection has been robustly demonstrated. Evidence
for this conclusion include (1) reduction of laboratory-associated
infections in vaccinated workers, (2) observation following initial
use of the vaccine in Brazil and other South American countries
that YF occurred only in unvaccinated persons, (3) rapid
disappearance of cases during YF vaccination campaigns initiated
during epidemics, (4) very few vaccine failures detected in any
endemic country, and (5) protection of rhesus monkeys against
virulent wild-type (WT) YF virus challenge by neutralizing
antibodies generated in response to YF vaccination11–13.
A booster dose requirement for YF vaccine was first put into
place in 1959 under the precursor to International Health
Regulations (IHR), International Sanitary Regulations, with booster
doses initially being required every 9 years based on available
data14,15. The booster dose interval was changed in 1965 to every
10 years based on limited evidence from two published studies
that showed neutralizing antibodies were present in most vaccine
recipients, including those who received the vaccine in childhood,
for at least 10 years after vaccination16,17. Starting in late 2011, the
WHO Strategic Advisory Group of Experts (SAGE) on Immunization
YF working group conducted a systematic review of ~17
unpublished and published studies that identified a very low
number of vaccine failures and high seropositivity rates following
vaccination over time18,19. From these additional, albeit observa-
tional data, SAGE concluded that a single primary dose of YF
vaccine is sufficient to confer sustained immunity and lifelong
protection against YF disease, and that a booster dose is not
needed, except for special populations (e.g., immunocompro-
mised and immunosuppressed)20. In May 2014, the World Health
Assembly adopted the recommendation to remove the 10-year
booster dose requirement from the IHR, which was enacted in
June 201621. In 2014, the United States Advisory Committee on
Immunization Practices (ACIP) YF vaccine working group con-
ducted a similar systematic review of YF vaccine immunogeni-
city10. However, since SAGE’s recommendation removed the IHR
requirement for boosters, ACIP working group reviewed the
available data to determine whether or not booster doses were
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needed as ACIP had never recommended a booster dose of the
vaccine before. Based on the available data, ACIP voted in 2015
that a single primary dose of YF vaccine provides long-lasting
protection and is adequate for most travelers22. However, as a
precautionary measure, it was noted that a booster dose may be
given to travelers who received their last dose of YF vaccine at
least 10 years previously and who will be in a higher-risk setting
based on season, location, activities, and duration of their travel.
This would include travelers who plan to spend a prolonged
period in endemic areas or those traveling to highly endemic
areas, such as rural West Africa during peak transmission season or
an area with an ongoing outbreak.
Subsequent to SAGE and ACIP recommendations that a single
dose of YF vaccine is sufficient to provide lifelong protection in
most individuals, several have questioned this decision23–26.
Furthermore, several recent studies have noted waning antibody
titers after vaccination and potential vaccine failures27–34. Below
we note what is known about vaccine immunity, review the
additional data that have been generated using full-dose YF
vaccine since the SAGE recommendation in 2013, and discuss next
steps to determine if booster doses of YF vaccine are needed.
WHAT CONSTITUTES YF VACCINE IMMUNITY?
One of the key questions to know whether or not YF vaccine
booster doses are needed is what constitutes protective vaccine
immunity. The closest correlate of protection that exists for YF
vaccination was established in one study of non-human primates
vaccinated with YF vaccine and then challenged with virulent WT
YF virus11. From this study, log10 neutralization index (LNI) of ≥0.7
was established as a potential cut-off for protective immunity with
51 (94%) of 54 surviving monkeys having a LNI ≥ 0.7. In
comparison, only one (8%) of 12 monkeys who died when
challenged had a LNI above 0.7. Currently, plaque reduction
neutralization tests (PRNTs) are used to establish the quantitative
titers of YF virus-specific antibodies as it uses less serum and is
typically easier to perform. Current studies typically report either
90% PRNT (PRNT90), PRNT80, or PRNT50 titers. Although a PRNT90
titer is more specific as it reduces the likelihood of positive results
due to cross-reactive neutralizing antibodies from other flavi-
viruses, it measures at the bottom of the S-shaped neutralization
curve, which leads to less variability and can lead to false-negative
results for lower virus-specific antibody titers35. PRNT50 titer are at
the midpoint or more linear portion of an S-shaped curve making
them higher, more variable and sensitive, but less specific. Most
clinical trials for flavivirus vaccines use a PRNT50 assay with a titer
of 1 in 10 as a correlate of protection36–38. However, LNI and PRNT
have never been formally compared using standardized reagents
to understand how they might relate. Furthermore, it is unclear if
neutralizing antibodies as measured using current assays are the
only correlate of protection. Our understanding of the role of cell-
mediated immunity in both the initial immunologic response, as
well as longer-term protection is advancing, but it also comes with
the uncertainty of what might represent protective types and
levels immunity that could prevent a person developing WT YF
disease. However, there is general agreement that the pool of
memory cells needs to be able to quickly proliferate when
challenged to protect an individual as the incubation period of YF
is typically short ranging from 3 to 6 days24,39,40.
The question of what constitutes vaccine immunologic memory
is not unique to YF vaccine. Smallpox vaccine also was utilized
before efficacy studies could be performed and the same
questions about vaccine immunity are present for live-
attenuated vaccines against vaccinia virus41. Although detection
of antibodies is used to denote protective immunity following
measles vaccination, it also has been documented that individuals
lacking detectable neutralizing antibodies can develop secondary
immune response with revaccination or exposure to measles virus
suggesting that alternative types of immunity exist42.
Currently, whether or not the absence of detectable neutralizing
antibodies represent an absence of protective immunity against
WT YF disease is a critical knowledge gap for YF immunity. As
noted above, it is also unclear what amount of antibody might be
needed to protect someone against developing a symptomatic
infection or viremia. Two studies have documented roughly one-
third of individuals with preexisting YF virus-specific neutralizing
antibodies fail to develop an anamnestic neutralizing antibody
response (i.e., ≥4-fold or greater increase in neutralization titers)
following a booster dose suggesting sterilizing immunity that is
correlated with higher pre-vaccination titers9,43. If it is correct that
an absence of detectable neutralizing antibodies following
primary immunization or the development of an amnestic
response following a booster vaccine dose means an absence of
protection for YF in a primary vaccinee, one might have expected
more cases of WT YF disease to be reported in children 4–10 years
post-vaccination33. However, epidemiologic data from the recent
outbreaks in Brazil indicate that very few cases of WT disease
occurred in children, with a lower incidence of WT disease in
children compared to adults5,44. Although this might be secondary
to who is being exposed or differences in clinical attack rate, the
recent outbreaks occurring near and in urban areas as well as the
notable occurrence of cases in women tend to suggest children
were likely exposed to the virus in these recent outbreaks. Finally,
the development of an amnestic response might not equate to a
lack of protection, particularly if the kinetics of the immunologic
response is fast enough to blunt the viremia due to a WT infection.
VACCINE FAILURES
Since 2013, there has been several reports of vaccine failures, one
in peer-reviewed literature plus epidemiologic reports issued by
public health authorities45–47. The published study, which has
been cited by others in editorials and reviews to support the need
for booster doses, came out in 2014 during the ACIP deliberations
and describe individuals having a history of YF vaccination who
later develop WT YF disease24,26,45. The ACIP YF vaccine working
group contacted the Brazil Ministry of Health (MOH) to verify that,
as stated, 459 (55%) of 831 YF cases in Brazil from 1973 to 2008
were vaccine failures, including 27 (3%) primary vaccine failures
(e.g., occurring after the first 10 days of vaccination but within the
first 10 years of vaccination) and 432 (52%) secondary vaccine
failures (e.g., occurring more than 10 years after vaccination
potentially due to waning antibody titers)45. The Brazil MOH
provided data to the working group noting that there were seven
vaccine failures in Brazil from 1973 to 2008; five constituting
primary vaccine failures, and two secondary vaccine failures
occurring at 20 and 27 years post vaccination10,45,48–50. Unfortu-
nately, there has never been a publication to clarify that the data
were not accurate and it continues to be cited as evidence to
support the need for booster doses33.
From data reported to the Pan American Health Organization
(PAHO) during 2000–2014 and published on their website, 83 (7%)
of 1164 of sylvatic YF cases reported from Bolivia, Brazil, Colombia,
and Peru occurred in individuals who reported receiving YF
vaccine46. More recently during the large outbreaks of YF in Brazil,
an epidemiologic bulletin noted at least 11 cases of WT YF in
individuals who were previously vaccinated and several more
cases have been noted during a recent meeting47,51. Unfortu-
nately, the information about these additional cases is very
limited. It is unknown if these cases represent primary or
secondary vaccine failures, whether and what confirmatory
laboratory testing was performed, and the underlying medical
history of the cases (e.g., immunosuppressed or compromised)
that might have impacted their initial immunologic response to
the vaccine or longer-term immunologic memory. Critically, given
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that YF IgM antibodies can persist for years following vaccina-
tion52, obtaining information about how the diagnosis of WT YF
disease was made is important to interpret these results.
Furthermore, it is important to note that not all individuals
respond to YF vaccination; there is a median seroconversion rate
of 99% (range 81–100%) in clinical trials8. Critically, for a state like
Minas Gerais in Brazil with a population over 20 million, this means
that even with 100% vaccination coverage more than 200,000
individuals who were vaccinated would fail to develop an immune
response to the vaccine and would be at risk for developing
disease if exposed.
SEROPOSITIVITY IN VACCINATED INDIVIDUALS
Since the SAGE recommendations in 2013, a number of articles
have been published related to the immune response seen
following YF vaccine, including cohorts of individuals in endemic
and non-endemic locations, of different ages, and at different time
points following vaccination. All studies used PRNT or microneu-
tralization test for the detection of neutralizing antibodies against
YF virus. However, the percent plaque reduction cut-off used and
the definition of seropositivity or protection varied by study such
that quantity of neutralizing antibodies measured in different
studies are difficult to compare35. Furthermore, several of the
studies did not use the international standard making comparison
of seropositivity or antibody concentrations between studies
further challenging53. The findings of these studies are
summarized below.
Humoral immunity in adults
There are data on longer-term humoral immunity for at least eight
distinct cohorts of adults in both YF endemic and non-endemic
areas of the world who received a full dose of YF vaccine (Table
1)27,28,31,32,54–57. Notably, there were no apparent differences
between studies undertaken in endemic and non-endemic
countries. In the first 5 years post-vaccination, seropositivity in
the cohorts was >90%. At ≥10 years post-vaccination, the rates of
seropositivity were generally lower ranging from 67% to 88%
using PRNT50–PRNT90, except for a small cohort of healthy
volunteers in the Netherlands where 97% (34/35) of individuals
vaccinated with a full-dose of the vaccine were seropositive at 10
years when measured with PRNT80
57. Interestingly, several of the
studies saw higher rates of seropositivity 30–35 years post-
vaccination compared to rates at 10–20 years post vaccina-
tion54,56. However, the number of individuals in the later
vaccination time points are quite limited and they likely received
an older vaccination formulation, which have differing quantities
of vaccine virus8, impacting the generalizability of these results.
Several other factors likely impact the overall rates of seroposi-
tivity in these studies, such as (1) proof of vaccination27, (2)
different seropositivity cut-offs28,32,35, (3) different individuals at
each time point post-vaccination often with different demo-
graphic (e.g., age of vaccination)27,28,30,56, (4) potential natural
boosting for residents and travelers to endemic areas, and (5)
potentially receiving an additional doses of YF vaccine31.
Humoral immunity in children
There have been four additional published studies with short-term
and long-term immunogenicity for children receiving a full dose
of YF vaccine (Table 2). The published studies contain cohorts of
children who received YF vaccination at 9–23 months of age. Of
the two studies published evaluating the seroconversion rate
following YF vaccination in children, the rates are highly variable
within one of the studies and between the studies58,59. In a study
of 595 children living in Colombia and Peru who received YF
vaccine alone or with a tetravalent dengue vaccine on a YF
vaccine backbone, the rate of seroconversion was noted to be
99.8–100% when measured by PRNT50 and titer ≥10
58. These rates
were similar though slightly higher than the rates seen in Mali
(95–98%) among children who received a meningococcal A (Men
A) vaccine either concurrently or serially with YF vaccine59.
However, in the same Men A vaccine study, children in Ghana only
achieved 68–79% seroconversion rates following YF vaccination.
This same trend in lower rates of detectable antibodies between
the two populations in the Men A study was seen when the
cohorts were followed up at 2–6 years post-vaccination34.
Seropositivity rates as low as 28% were reported for children in
Ghana at 2.3 years post-vaccination, though the rate increased at
6 years post-vaccination to 43%, compared to 50% seropositivity
among the children in Mali at 4.5 years post-vaccination34. When
demographic (age of vaccination, sex), vaccination and exposure
history (season of vaccination and pre-vaccination titers), and
nutritional status were compared between the children in Mali
and Ghana, no significant differences were identified to explain
the different rates of seropositivity between these two popula-
tions60. In the second study evaluating longer-term immunity in
different cohorts of children in Brazil up to 10 years post-
vaccination, a substantial decline was noted in the seropositivity
rates over time33. Using a titer ≥10 with PRNT50, 54% of children
were not seropositive at 7 years post-vaccination. Although the
rates of seropositivity increased when using a lower titer cut-off
(PRNT ≥ 5), 36% of children at 7 years post-vaccination lacked
detectable neutralizing antibodies.
One potential explanation for the varying immune response
both initially and potentially longer-term among the pediatric
studies could be the age at which the children received their
vaccine. Younger age groups might be expected to have a less
robust initial immune response, potential immunologic inter-
ference from maternal antibodies, or more concomitant infections
lead to a decreased immune response61,62. The cohorts in Mali,
Ghana, and some of the children in the Brazil study received YF
vaccine at 9 months of age. This is compared to children in
Colombia and Peru who received the vaccine at 12 months of age
and others in the Brazil cohort who were as old as 23 months
when they were vaccinated. However, when the age of vaccina-
tion was assessed by the ACIP YF working group relative to the
seroconversion rates, the analysis of results from aggregated
studies found no difference in seroconversion rates when the
children were vaccinated at 9 months of age compared to
12 months10,22.
With these new pediatric data, there are seemingly more
questions than answers to the variability of the results between
the pediatric cohorts. The authors of the studies and associated
editorials question what contributes to the variability in results
hypothesizing that it could be due to differences in immune
microenvironment, vaccine substrains used, how the samples
were handled, the test used, and potential difference in vaccine
handling33,61,63,64. Furthermore, in both Ghana and Brazil, the
authors questioned whether or not children had received another
dose of the vaccine as the proportion seropositive was higher at
later time points33,34.
Additional immunogenicity data
Since 2013, several studies have been published regarding cellular
immunity, including CD8+, CD4+, and memory phenotypes,
formed in response to YF vaccine30,54,55,65. However, the specific
impact of alternative types of immunologic memory and their role
in protecting persons against disease is not well-characterized
or known.
NEXT STEPS
The studies published since SAGE and ACIP made their
recommendation that one dose of YF vaccine is sufficient to
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provide lifelong protection in most individuals provide additional
data on YF vaccine immunity. Given the heterogeneity of results,
in particular for the pediatric cohorts, further studies would be
welcomed.
However, the basic questions that were debated in the
discussions of both SAGE and ACIP still remain, how durable is
the immunity elicited by YF vaccine and what constitutes
protective immunity against YF virus infection and disease? To
truly address these questions, additional research and data are
needed. Increased transparency and sharing of information on
potential vaccine failures are critical to better understand of the
>800 million doses the vaccine that have been administered how
many might have failed to provide both short-term and long-term
protective immunity. With this is the need to continue improving
and strengthening YF disease surveillance and laboratory
testing66, not only to detect possible vaccine failures but also to
obtain samples early enough to make a definitive diagnosis of WT
disease by molecular testing. In addition, every effort must be
made to ascertain the vaccination status of the patient. As noted
above, using standards and evaluating the correlation between
neutralization titers determined by LNI and PRNT would improve
our ability to compare studies and begin to set thresholds as to
what antibodies levels are needed to potentially prevent WT
disease. Furthermore, additional research is needed to determine
the kinetics of the immune response when a vaccinee receives a
booster vaccine dose or has a WT infection (e.g., does an amnestic
response mean a lack of adequate protection?) and to validate the
immune correlate of protection following YF vaccination using
more modern knowledge and techniques (e.g., assessing the role
of cellular immunity). WHO currently plans to receive input from
subject matter experts on how best to proceed with measuring YF
vaccine immunity in a consistent manner to allow for compar-
ability between studies.
Overall, we expect the debate of whether or not to give booster
doses of YF vaccine to continue in lieu of more data. However, one
clear public health action that can and should be taken now is to
improve YF vaccination coverage among children living in at risk
areas. Based on WHO and UNICEF estimates of vaccine coverage
Table 1. Seropositivity following full-dose yellow fever (YF) vaccination in adults.






















































































































Obs observational, PRNT plaque reduction neutralization test, IU international units, m months, y years.
aData presented in italic are subsets of total.
bWieten et al68. also published data on 30 healthy and 15 immunocompromised individuals vaccinated at median 9 years (range 0–22 years) and median 7
years (range 0–18 years) previously, respectively; it is not known if there is overlap between the healthy population and those included in the study in the
table above. Antibody titers were detected (IU/mL ≥ 0.5) in 15/15 (100%) immunocompromised and 29/30 (97%) healthy individuals.
cData from vaccinees were presented in a separate paper using a lower cut-off of 2.7 mIU/mL for seropositivity. The proportion seropositive was higher for all
groups: 99% seropositivity at 1–4 years post-vaccination; 88% seropositivity at 5–9 years; 86% seropositivity at 10–11 years; and 90% seropositivity at
≥12 years.
dCohort contained individuals who received one dose (n= 59); two or more doses (n= 17); or unknown number of doses (n= 18) of YF vaccine. Data not
broken down by time post-vaccination and number of doses other than to note there was no difference in the seropositivity by time post-vaccination for
those receiving one dose.
eThe 1-month and 10-month results data were obtained from original study paper by Martins et al. 201369. Only includes individuals who received a full dose
of the vaccine.
fOnly includes persons who received full dose of YF vaccine and who were seropositive at 1-month and 10-month follow-up visits.
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(WUENIC), YF vaccination rates among children living in YF endemic
areas ranges from 42% to 97% (median of 85%) in the Americas
and 29–94% (median: 68%) in Africa67. The current large outbreaks
of measles throughout the world, including in YF endemic areas
where the vaccines are often given at the same visit, reinforces poor
YF vaccination rates that exist among children. If children do not
even receive their first dose of YF vaccine, it is hard to focus on
whether they might need a booster dose. We encourage
researchers, clinicians, and public health officials to continue to
evaluate and publish quality data on YF vaccine immunity and
vaccine failures to inform public health policy related to YF vaccine
use and optimize our ability to prevent YF.
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G Ghana, M Mali, Obs observational, PRNT plaque reduction neutralization test, RCT randomized control trial, IU international units, m months, y years.
aNumbers represent the number of children with immunogenicity results included in the respective countries (denominator) and proportions represent those
seroconverting; 64–68% of children in Ghana (N= 38) and 90–98% of children in Mali (n= 12) were seropositive at baseline and had ≥2-fold increase in
antibody titer.
bData from vaccinees were also presented in the same paper using any detectable antibodies. The proportion of seropositive was higher for all groups: 39%
(172/436) at 2.3 years in Ghana; 70% (409/587) seropositivity at 4.5 years in Mali; and 51% (223/436) seropositivity at 6 years in Ghana.
cSame data presented in Campi-Azevedo et al. (2019)55.
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